KDM1A and acute myeloid leukemia: Previous studies linked LSD1 aberrations with multiple malignancies, and the most promising results of LSD1 inhibitors were observed in acute myeloid leukaemia and SCLC [102], with GSK-2879552 and RG6016 representing a promising novel epigenetic approach for SCLC.